October 12, 2012

Genzyme Presents Second Phase III Study of Once-daily Oral AUBAGIO® (teriflunomide) Confirming Significant Impact on Disability

- AUBAGIO 14 mg is the Only Oral MS Therapy to Significantly Delay Progression of Disability Across Two Phase III Studies -

 

Genzyme Presents Second Phase III Study of Once-daily Oral AUBAGIO® (teriflunomide) Confirming Significant Impact on Disability
- AUBAGIO 14 mg is the Only Oral MS Therapy to Significantly Delay Progression of Disability Across Two Phase III Studies -

Paris, France – October 12, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that key data from the TOWER trial were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). In the study, once-daily, oral AUBAGIO® 14 mg significantly reduced the annualized relapse rate and slowed progression of disability in patients with relapsing forms of multiple sclerosis (MS) compared to placebo. In addition, the proportion of patients treated with AUBAGIO® who were relapse-free was significantly higher compared to placebo.